Meta AnalysisID 3866
藻蓝蛋白对糖尿病相关代谢紊乱的影响：系统评价
CRD42022307522
Does phycocyanin affect diabetes-related metabolic disorders? Context and rationale Phycocyanin (PC) is the most abundant protein component in cyanobacteria like Spirulina platensis, accounting for 15-40% of their dried
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Ingredient: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 3866
- Evidence Id
- 12424
- Core Evidence Id
- 12424
- Source Meta Analysis Id
- 3821
- Herb2 Meta Analysis Id
- HBMA003821
- Crd Id
- CRD42022307522
- Title
- The effect of phycocyanin on diabetic-related metabolic disorders: A systematic review
- Review Question
- Does phycocyanin affect diabetes-related metabolic disorders? Context and rationale Phycocyanin (PC) is the most abundant protein component in cyanobacteria like Spirulina platensis, accounting for 15-40% of their dried biomass . Phycocyanin has been proven to have antioxidant, anti-inflammatory, and antioxidant effects in several studies. Phycocyanin is also frequently utilized as a natural color in food and cosmetics, and pharmaceutical products . Studies in this area confirm the anti-diabetic effects of phycocyanin and state that it can be used for diabetes mellitus (DM) therapy . In addition, they report that phycocyanin reduces the pathological features of diabetes . Therefore, this article will investigate the effect of phycocyanin on biomarkers of glycemic control and glucose metabolism, including FBS, insulin, Insulin resistance, β-cell function, and pathologic feature in animal and cellular studies.
- Study Type Included
- Inclusion criteria: All studies, including the animal studies that examined the effects of phycocyanin on the parameters related to diabetes, are included in this study. Exclusion criteria: The case report, case series, reviews, and studies with incomplete data will be excluded.
- Condition Being Studied
- Participant
- Animal
- Inclusion criteria: All animal models of diabetes treated with phycocyanin as well as their comparison groups. We will report the species, sex and age of these animals as mentioned by the researchers. Exclusion criteria: Mice/rats that did not receive our intervention will not be reported.
- Human Disease Modelled
- Diabetes mellitus (DM) is a metabolic syndrome defined by high blood sugar levels. It is one of the most common chronic diseases globally, and its prevalence is developing. According to the International Diabetes Federation, almost 464 million adults had diabetes in 2019; diabetes is expected to impact 700 million people by 2045. Diabetes caused 1.5 million deaths in 2019, making it the seventh most significant cause of mortality. As a result, finding safe, effective, and improved hypoglycemic agents has been, and continues to be, an active research topic
- Intervention
- Inclusion criteria: In this study, only groups of animals that received our desired intervention, phycocyanin, will be examined. In relation to this intervention, the dose (mg / kg body weight), frequency of use (daily, weekly, etc.), administration route (orally /IP etc.), and duration of use (weeks or days) will be included in the study. All timings, frequencies and dosages of intervention will be included. Exclusion criteria: Interventions other than phycocyanin are excluded.
- Comparator Control
- Inclusion criteria: Untreated diabetic animals (In most studies). Exclusion criteria: Other control groups (non-diabetic groups, diabetic drug treatment groups)
- Main Outcome
- Outcome Measure
- Inclusion criteria: The results of the study will be evaluated in which diabetic parameters such as FINS (fasting serum insulin), GSP (glycosylated serum protein), GHb (glycosylated hemoglobin) and FBG (fasting serum insulin) are measured (primary outcome), also; molecular mechanisms associated with the anti-diabetic effects of phycocyanin will be reported as secondary outcomes. Exclusion criteria: Other results reported in studies.
- Additional Outcome
- Study Method
- Keyword
- Animals; Diabetes Mellitus; Metabolic Diseases; Phycocyanin
- Contact
- Zahra Ataie [email protected]
- Organisational Affiliation
- Alborz University of Medical Science https://abzums.ac.ir/en-US/DouranPortal/1/page/Home
- Funding Source
- Other Selection Criteria
- Inclusion criteria: there will be language limitations, publications from 2000 to 2022. and case reports, case series, reviews and studies with incomplete data will be excluded.
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Animal model review
- Language
- English
- Country
- Iran
- Review Stage
- Review Ongoing
- First Submission Date
- 2022-01-28
- Registration Date
- 2022-04-26
- Anticipated Start Date
- 2022-01-01
- Anticipated Completion Date
- 2022-06-30
- Title Cn
- 藻蓝蛋白对糖尿病相关代谢紊乱的影响：系统评价
- Title En
- The effect of phycocyanin on diabetic-related metabolic disorders: A systematic review
- Bilingual Status
- complete